06Selected for 2025 Scale-up TIPS R&D Project: “Process optimization and regulatory strategy for CB-11, an advanced biopharmaceutical for malignant brain tumor”
05Selected for Advanced Regenerative Medicine Clinical Study: “Clinical safety and tolerability study of MSC11FCD with suicide gene in newly diagnosed glioblastoma patients”
03Certified as a Women-Owned Business – Ministry of SMEs and Startups
2024
12Series B Investment attracted (₩5 billion, Laguna Investment and 2 other VCs)
09Selected for University-Industry Collaboration Platform Project: “Preclinical study of gene-modified MSCs using non-human primates”
09Selected for National New Drug Development Project: “Discovery of gene-cell therapy candidates for solid tumors”
2021
12Series A Investment attracted (₩5 billion, Laguna Investment and 3 other VCs)
09Selected for Regenerative Medicine R&D Program: “Preclinical study of CB-31, gene-modified MSCs for chronic stroke”
04Venture Business Certification – Ministry of SMEs and Startups
03Initiation of Investigator-Initiated Trial (IIT) for brain tumor cell therapy
2020
12 Selected for BIG3 Promising Start-up Support Project: “Optimization of manufacturing process for gene-modified MSCs for brain diseases”
09Selected for Jeonbuk Techno Park Follow-up Advancement Project: “Production of gene-activated MSCs for brain activation”
05Selected for BIG3 Promising Start-up Support Project: “Safety evaluation assay for gene-modified stem cell therapy”
04 Selected for Advanced Medical Technology Development Project: “Platform and common technologies to enhance quality and competitiveness of cell therapies”
2019
12Patent transferred – Ajou University Industry-Academic Cooperation Foundation
10Pre-A Investment attracted (₩1.17 billion, N4U Holdings and 2 other investors, TIPS-linked)
09Applied for TIPS (Operated by Chungbuk Center for Creative Economy & Innovation)
08 Certified as an Affiliated Research Institute – Korea Industrial Technology Association
05 Selected for 전북특구 기술이전사업화 Project: “Performance evaluation model for gene-activated MSC therapy and defining target product profile”
2018
11Selected for Bio-Medical Technology Development Project: “Development of MSC-based therapy for chronic stroke”
